Evidence map›Paper›PMID 34712029›Full record

ReviewWorld journal of gastroenterology2021

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.

Farah Albader, Petra Anna Golovics, Lorant Gonczi, Talat Bessissow, Waqqas Afif, Peter Laszlo Lakatos

Open access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Therapeutic drug monitoring for biological medications in inflammatory bowel disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Farah AlbaderDepartment of Internal Medicine, McGill University, Montreal H3G1A4, Quebec, Canada.
Petra Anna GolovicsDivision of Gastroenterology, Hungarian Defence Forces, Medical Centre, Budapest H-1062, Hungary.
Lorant GoncziFirst Department of Medicine, Semmelweis University, Budapest H-1083, Hungary.
Talat BessissowDivision of Gastroenterology, McGill University Health Centre, Montreal H3G 1A4, Quebec, Canada.
Waqqas AfifDivision of Gastroenterology, McGill University, Montreal H3G 1A4, Quebec, Canada.
Peter Laszlo LakatosDivision of Gastroenterology, McGill University, Montreal H3G 1A4, Quebec, Canada. kislakpet99@gmail.com.
Semmelweis University · HUZrínyi Miklós National Defence University · HUJackson and Tull (United States) · USMcGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic condition that significantly affects the quality of life of its patients. Biologic drugs have been the mainstay treatment in the management of IBD patients but despite their significant contribution, there remains a proportion of patients that do not respond or lose response to treatment. Therapeutic drug monitoring (TDM) involves measuring levels of serum drug concentrations and anti-drug antibodies. TDM of biologic drugs initially emerged to understand treatment failure in other immune mediated inflammatory diseases. This was then introduced in IBD to rationalize primary non-response or secondary loss of response, given that low serum drug concentrations or the formation of anti-drug antibodies are variably associated with treatment failure. The aim of this narrative review is to provide an overview regarding the current use of TDM in clinical practice and to present the evidence available regarding its use in both proactive and reactive clinical settings in preventing and managing treatment failure. This review also presents the existing evidence regarding the association of various clinical outcomes with specific thresholds of drug concentrations, in everyday practice. A narrative review of published articles and conference abstracts regarding the use of TDM in IBD management, through an electronic search using PubMed and ScienceDirect. TDM has proven to be superior and more cost effective in guiding management of patients with treatment failure compared to empiric dose escalation or change in treatment. Despite a trend towards an association between clinical outcomes and drug concentrations, proactive TDM based strategies have not been shown to achieve clear benefit in long-term outcomes. In the clinical setting, TDM has proven to be useful in managing IBD patients, and its use in the reactive setting, as an additional tool to help manage patients with treatment failure, is being promoted as newer guidelines and consensus groups implement TDM as part of the management plan.

Indexed as

Biological ProductsInflammatory Bowel DiseasesDrug MonitoringGastrointestinal AgentsHumansQuality of LifeBiological ProductsGastrointestinal AgentsBiologic therapiesInflammatory bowel diseaseLoss of responseProactiveReactiveTherapeutic drug monitoring

Identifiers

PMID34712029
PMCPMC8515794
OpenAlexW3203232434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.